IMRX fundamentals
An in-depth look to Immuneering Corporation operating, investing, and financing activities
IMRX free cash flow for Q2 24 is -11.56 M USD. For 2023, IMRX free cash flow was -49.31 M USD and operating cash flow was -48.97 M USD.
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: USD
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
TTM